Bloomberg yesterday evening reported that Japan-based Astellas Pharma is exploring selling its Central and Eastern Europe assets, worth at least $500m.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,